Your browser doesn't support javascript.
loading
Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification.
Pellegrino, Benedetta; Herencia-Ropero, Andrea; Llop-Guevara, Alba; Pedretti, Flaminia; Moles-Fernández, Alejandro; Viaplana, Cristina; Villacampa, Guillermo; Guzmán, Marta; Rodríguez, Olga; Grueso, Judit; Jiménez, Jose; Arenas, Enrique J; Degasperi, Andrea; Dias, João M L; Forment, Josep V; O'Connor, Mark J; Déas, Olivier; Cairo, Stefano; Zhou, Yinghui; Musolino, Antonino; Caldas, Carlos; Nik-Zainal, Serena; Clarke, Robert B; Nuciforo, Paolo; Díez, Orland; Serres-Créixams, Xavier; Peg, Vicente; Espinosa-Bravo, Martín; Macarulla, Teresa; Oaknin, Ana; Mateo, Joaquin; Arribas, Joaquín; Dienstmann, Rodrigo; Bellet, Meritxell; Oliveira, Mafalda; Saura, Cristina; Gutiérrez-Enríquez, Sara; Balmaña, Judith; Serra, Violeta.
Afiliação
  • Pellegrino B; Department of Medicine and Surgery, University of Parma, Italy.
  • Herencia-Ropero A; Medical Oncology and Breast Unit, University Hospital of Parma, Italy.
  • Llop-Guevara A; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Pedretti F; Department of Biochemistry and Molecular Biology, Autonomous University of Barcelona, Barcelona, Spain.
  • Moles-Fernández A; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Viaplana C; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Villacampa G; Department of Biochemistry and Molecular Biology, Autonomous University of Barcelona, Barcelona, Spain.
  • Guzmán M; Hereditary Cancer Genetics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Rodríguez O; Oncology Data Science Group (ODysSey Group), Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Grueso J; Oncology Data Science Group (ODysSey Group), Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Jiménez J; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Arenas EJ; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Degasperi A; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Dias JML; Molecular Oncology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Forment JV; Growth Factors Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • O'Connor MJ; CIBERONC, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Déas O; Academic Department of Medical Genetics, University of Cambridge, Addenbrooke's Treatment Centre, Cambridge Biomedical Campus, Cambridge, United Kingdom.
  • Cairo S; MRC Cancer Unit, Hutchison/MRC Research Centre, Cambridge Biomedical Campus, University of Cambridge, Cambridge, United Kingdom.
  • Zhou Y; Academic Department of Medical Genetics, University of Cambridge, Addenbrooke's Treatment Centre, Cambridge Biomedical Campus, Cambridge, United Kingdom.
  • Musolino A; MRC Cancer Unit, Hutchison/MRC Research Centre, Cambridge Biomedical Campus, University of Cambridge, Cambridge, United Kingdom.
  • Caldas C; Oncology iMED, AstraZeneca, Cambridge, United Kingdom.
  • Nik-Zainal S; DDR Biology Group, Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Clarke RB; XenTech, Evry, France.
  • Nuciforo P; XenTech, Evry, France.
  • Díez O; TESARO: A GSK company, Waltham, Massachusetts.
  • Serres-Créixams X; Department of Medicine and Surgery, University of Parma, Italy.
  • Peg V; Medical Oncology and Breast Unit, University Hospital of Parma, Italy.
  • Espinosa-Bravo M; Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge, Cambridge, United Kingdom.
  • Macarulla T; Breast Cancer Programme, Cancer Research UK (CRUK) Cambridge Cancer Centre, Cambridge, United Kingdom.
  • Oaknin A; Academic Department of Medical Genetics, University of Cambridge, Addenbrooke's Treatment Centre, Cambridge Biomedical Campus, Cambridge, United Kingdom.
  • Mateo J; MRC Cancer Unit, Hutchison/MRC Research Centre, Cambridge Biomedical Campus, University of Cambridge, Cambridge, United Kingdom.
  • Arribas J; Manchester Breast Centre, Division of Cancer Sciences, University of Manchester, Oglesby Cancer Research Building, Manchester, United Kingdom.
  • Dienstmann R; Molecular Oncology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Bellet M; Hereditary Cancer Genetics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Oliveira M; Area of Clinical and Molecular Genetics, Vall d'Hebron University Hospital, Barcelona, Spain.
  • Saura C; Department of Radiology, Vall d'Hebron University Hospital, Autonomous University of Barcelona, Barcelona, Spain.
  • Gutiérrez-Enríquez S; Pathology Department, Vall d'Hebron University Hospital, Barcelona, Spain.
  • Balmaña J; Breast Surgical Unit, Breast Cancer Center, Vall d'Hebron University Hospital, Autonomous University of Barcelona, Barcelona, Spain.
  • Serra V; Gastrointestinal and Endocrine Tumors Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
Cancer Res ; 82(8): 1646-1657, 2022 04 15.
Article em En | MEDLINE | ID: mdl-35425960
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Neoplasias da Mama Tipo de estudo: Clinical_trials / Diagnostic_studies / Prognostic_studies Limite: Female / Humans Idioma: En Revista: Cancer Res Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Itália
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Neoplasias da Mama Tipo de estudo: Clinical_trials / Diagnostic_studies / Prognostic_studies Limite: Female / Humans Idioma: En Revista: Cancer Res Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Itália